Home › Funds › Rosalind Advisors, Inc. › XERS

Rosalind Advisors, Inc. position in XERS

XERIS BIOPHARMA HOLDINGS INC · Health Care

Rosalind Advisors, Inc. reported holding 400,000 shares of XERS (XERIS BIOPHARMA HOLDINGS INC) in its Q3 2026 13F filing — a position valued at US$160K, representing 0.07% of its reported portfolio and ranking #35 among its reported holdings. Rosalind Advisors, Inc. has disclosed XERS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)400.00K sh
Reported value held$160.00K
Portfolio Weight0.07%
First reportedQ4 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Rosalind Advisors, Inc.'s XERS position evolved

Rosalind Advisors, Inc. first disclosed a stake in XERS in Q4 2023 at 3,543,685 shares (US$8.3M). The position peaked in Q2 2026 at 2,908,981 shares, worth US$23.0M. Across 12 filings, Rosalind Advisors, Inc. increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 400,000 shares valued at US$160K — a reduction of -2,508,981 shares quarter over quarter.. Notable position changes include a 53% increase in Q1 2026 (shares rose 37% over the following quarter), a 86% trim in Q3 2026 (shares rose 74% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 3.54M $8.33M New
Q1 2024 2.82M $6.23M Reduce
Q2 2024 3.12M $7.02M Add
Q3 2024 3.10M $8.85M Hold
Q4 2024 3.10M $10.53M Hold
Q1 2025 2.50M $13.70M Reduce
Q2 2025 2.16M $10.07M Reduce
Q3 2025 1.80M $14.62M Reduce
Q4 2025 2.11M $16.58M Add
Q1 2026 3.23M $18.74M Add
Q2 2026 2.91M $23.04M Reduce
Q3 2026 400.00K $160.00K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XERS and 13F data

XERS (XERIS BIOPHARMA HOLDINGS INC) is a Health Care company. 47 other funds we track also report a position in XERS — the largest reported positions include Polar Asset Management Partners Inc. (US$28.8M), Parkman Healthcare Partners LLC (US$15.7M), Vilga Financial Planning LLC (US$10.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XERS

All XERS fund holders →

FAQ

How long has Rosalind Advisors, Inc. held XERS?

Rosalind Advisors, Inc. has disclosed XERS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Rosalind Advisors, Inc.'s current position in XERS?

As of Q3 2026, Rosalind Advisors, Inc. holds 400.00K shares of XERS (XERIS BIOPHARMA HOLDINGS INC), valued at $160.00K, representing 0.07% of its reported portfolio and ranking #35.

Has Rosalind Advisors, Inc. been buying or selling XERS?

In the latest 13F filing (Q3 2026), Rosalind Advisors, Inc. reduced its position in XERS. The position peaked in Q2 2026 at 2.91M shares.

Which other funds hold XERS?

Other major institutional holders of XERS include Polar Asset Management Partners Inc., Parkman Healthcare Partners LLC, Vilga Financial Planning LLC, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.